Haidong Wang
Research Subjects
Haidong Wang has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Jingyao Li
Department of Thoracic Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China
10 shared publicationsYang Qiu
9 shared publicationsTao Jing
Department of Vasculocardiology, Southwest Hospital, Army Medical University, (Third Military Medical University), Chongqing, China
8 shared publicationsYi Liao
Department of Thoracic Surgery, Southwest Hospital, Army Medical University, (Third Military Medical University), Chongqing, China
8 shared publicationsShixin Zhang
Department of Thoracic Surgery, Southwest Hospital, Army Medical University, (Third Military Medical University), Chongqing, China
7 shared publicationsMeng Tang
Department of Thoracic Surgery, Southwest Hospital, Army Medical University, (Third Military Medical University), Chongqing, China
6 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (3) , 46
A radiomics nomogram integrated with radiological features for preoperative prediction of lung nodule invasiveness: comparison with Lung-RADS
Background: Preoperative identification of early-stage lung adenocarcinoma, particularly minimal lesions, holds critical implications for clinical decision-making. However, accurate diagnosis of pulmonary nodules’ malignancy remains challenging when relying solely on conventional clinical parameters or radiological features, due to the lack of specificity in certain instances of early lesions. This study aims to develop a nodule-level composite model using radiomics methods and compare its performance with the Lung CT Screening Reporting and Data System (Lung-RADS) in predicting the invasiveness using preoperative low-dose computed tomography (LDCT) scan with 1 mm slice thickness. Methods: From June 2019 to October 2023, the patients who were pathologically diagnosed with the initial primary lung nodules were enrolled in the retrospective cohort. To predict invasiveness of nodule, nodule-level models, including radiomics, radiological, and combined models, were developed to categorize the nodules into the invasiveness and non-invasiveness groups. Radiomics features were extracted from the tumor region to develop a radiomics model after a three-stage feature reduction procedure, resulting in a Radscore for each nodule. The nodules were randomly divided into two groups, with a ratio of 7:3. The area under the receiver operating characteristic curve (AUC), accuracy, and other relevant measures were employed to assess the models’ performance and discriminative ability. A nomogram that combines optimal radiomics and clinical-radiological features was compared to Lung-RADS using various evaluation methods, including calibration curve analysis, decision curve analysis (DCA), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: A total of 393 patients were enrolled, including 67 with multiple nodules. Altogether, 487 nodules were analysed, comprising 374 in the invasiveness and 113 in the non-invasiveness group. The radiological model identified two risk factors: nodule type and a vessel convergence sign. The nomogram achieved a training-set AUC of 0.91, surpassing the Lung-RADS system (AUC: 0.669) in nodule assessment. Notably, significant improvements in NRI and IDI, as well as higher net benefits, were shown by the DCA. Conclusions: The nomogram based on radiomics and radiological features offers supplementary information for preoperative prediction of the invasiveness of lung nodules, surpassing both the commonly used Lung-RADS and single models in guiding diagnosis and treatment strategies for lung nodules.
- 1 March 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (3) , 46
Open AccessA radiomics nomogram integrated with radiological features for preoperative prediction of lung nodule invasiveness: comparison with Lung-RADS
Background: Preoperative identification of early-stage lung adenocarcinoma, particularly minimal lesions, holds critical implications for clinical decision-making. However, accurate diagnosis of pulmonary nodules’ malignancy remains challenging when relying solely on conventional clinical parameters or radiological features, due to the lack of specificity in certain instances of early lesions. This study aims to develop a nodule-level composite model using radiomics methods and compare its performance with the Lung CT Screening Reporting and Data System (Lung-RADS) in predicting the invasiveness using preoperative low-dose computed tomography (LDCT) scan with 1 mm slice thickness. Methods: From June 2019 to October 2023, the patients who were pathologically diagnosed with the initial primary lung nodules were enrolled in the retrospective cohort. To predict invasiveness of nodule, nodule-level models, including radiomics, radiological, and combined models, were developed to categorize the nodules into the invasiveness and non-invasiveness groups. Radiomics features were extracted from the tumor region to develop a radiomics model after a three-stage feature reduction procedure, resulting in a Radscore for each nodule. The nodules were randomly divided into two groups, with a ratio of 7:3. The area under the receiver operating characteristic curve (AUC), accuracy, and other relevant measures were employed to assess the models’ performance and discriminative ability. A nomogram that combines optimal radiomics and clinical-radiological features was compared to Lung-RADS using various evaluation methods, including calibration curve analysis, decision curve analysis (DCA), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: A total of 393 patients were enrolled, including 67 with multiple nodules. Altogether, 487 nodules were analysed, comprising 374 in the invasiveness and 113 in the non-invasiveness group. The radiological model identified two risk factors: nodule type and a vessel convergence sign. The nomogram achieved a training-set AUC of 0.91, surpassing the Lung-RADS system (AUC: 0.669) in nodule assessment. Notably, significant improvements in NRI and IDI, as well as higher net benefits, were shown by the DCA. Conclusions: The nomogram based on radiomics and radiological features offers supplementary information for preoperative prediction of the invasiveness of lung nodules, surpassing both the commonly used Lung-RADS and single models in guiding diagnosis and treatment strategies for lung nodules.
- Open Access
- 8 January 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (1) , 32
AI-MDT: an automatic and intelligent multidisciplinary team consultations platform for lung cancer diagnosis
Purpose: Multidisciplinary team (MDT) consultations are crucial for managing pulmonary nodules, yet face challenges in efficiency, evidence-based decision support, and data utilization within the MDT process. We present an integrated artificial intelligence (AI)-MDT platform that serves as an assistive tool for lung cancer MDT workflows by incorporating AI across various processes.The aim of this study is to evaluate the clinical utility and preliminary efficacy of the AI-MDT platform. Methods: The platform comprises three core modules: process automation, intelligent decision support, and diagnostic assistance. It integrates a real-time, evidence-based knowledge base powered by large language models and deep learning, with computer vision for automatic lesion detection and feature analysis. A web-based interface allows users to interact seamlessly with the AI-MDT platform. Results: Since its implementation in November 2023 at a tertiary Grade A hospital in China, the platform has been involved in 879 consultations, including 811 patients. AI-generated diagnostic recommendations were utilized 852 times, and decision-making support was used in 744 cases. The platform significantly increased consultation volume, reduced expert time, and enhanced data utilization compared to traditional MDT. Conclusions: It offers clinicians tools to improve diagnostic quality and work efficiency, highlighting its significant clinical application value. These findings suggest that the proposed platform contributes to the emerging research on advances precision lung cancer management by integrating a continually updated evidence base and intelligent imaging methodologies, having potential implications for MDT processes across various medical specialties.
- 8 January 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (1) , 32
Open AccessAI-MDT: an automatic and intelligent multidisciplinary team consultations platform for lung cancer diagnosis
Purpose: Multidisciplinary team (MDT) consultations are crucial for managing pulmonary nodules, yet face challenges in efficiency, evidence-based decision support, and data utilization within the MDT process. We present an integrated artificial intelligence (AI)-MDT platform that serves as an assistive tool for lung cancer MDT workflows by incorporating AI across various processes.The aim of this study is to evaluate the clinical utility and preliminary efficacy of the AI-MDT platform. Methods: The platform comprises three core modules: process automation, intelligent decision support, and diagnostic assistance. It integrates a real-time, evidence-based knowledge base powered by large language models and deep learning, with computer vision for automatic lesion detection and feature analysis. A web-based interface allows users to interact seamlessly with the AI-MDT platform. Results: Since its implementation in November 2023 at a tertiary Grade A hospital in China, the platform has been involved in 879 consultations, including 811 patients. AI-generated diagnostic recommendations were utilized 852 times, and decision-making support was used in 744 cases. The platform significantly increased consultation volume, reduced expert time, and enhanced data utilization compared to traditional MDT. Conclusions: It offers clinicians tools to improve diagnostic quality and work efficiency, highlighting its significant clinical application value. These findings suggest that the proposed platform contributes to the emerging research on advances precision lung cancer management by integrating a continually updated evidence base and intelligent imaging methodologies, having potential implications for MDT processes across various medical specialties.
- 2 July 2025
- Published by Springer Nature
- p. 274-288
AIM-MIL: Adversarial Instance Mining for Robust Multi-instance Learning in Whole Slide Image Classification
- 2 July 2025
- Published by Springer Nature
- p. 274-288
AIM-MIL: Adversarial Instance Mining for Robust Multi-instance Learning in Whole Slide Image Classification
- Open Access
- 10 May 2023
- Published by Springer Nature in Thrombosis Journal
- Vol. 21 (1) , 1-10
Postoperative intermittent pneumatic compression for preventing venous thromboembolism in Chinese lung cancer patients: a randomized clinical trial
Background: Postoperative lung cancer patients belong to the high-risk group for venous thromboembolism (VTE). The standardized preventive measures for perioperative VTE in lung cancer are not perfect, especially for the prevention and treatment of catheter-related thrombosis (CRT) caused by carried central venous catheters (CVCs) in lung cancer surgery. Patients and methods: This study included 460 patients with lung cancer undergoing video-assisted thoracic surgery (VATS) in our center from July 2020 to June 2021. Patients were randomized into two groups, and intraoperatively-placed CVCs would be carried to discharge. During hospitalization, the control group was treated with low-molecular-weight heparin (LMWH), and the experimental group with LMWH + intermittent pneumatic compression (IPC). Vascular ultrasound was performed at three time points which included before surgery, before discharge, and one month after discharge. The incidence of VTE between the two groups was studied by the Log-binomial regression model. Results: CRT occurred in 71.7% of the experimental group and 79.7% of the control group. The multivariate regression showed that the risk of developing CRT in the experimental group was lower than in the control group (Adjusted RR = 0.889 [95%CI0.799–0.989], p = 0.031), with no heterogeneity in subgroups (P for Interaction > 0.05). Moreover, the fibrinogen of patients in the experimental group was lower than control group at follow-up (P = 0.019). Conclusion: IPC reduced the incidence of CRT during hospitalization in lung cancer patients after surgery. Trial registration: No. ChiCTR2000034511.
- 10 May 2023
- Published by Springer Nature in Thrombosis Journal
- Vol. 21 (1) , 1-10
Open AccessPostoperative intermittent pneumatic compression for preventing venous thromboembolism in Chinese lung cancer patients: a randomized clinical trial
Background: Postoperative lung cancer patients belong to the high-risk group for venous thromboembolism (VTE). The standardized preventive measures for perioperative VTE in lung cancer are not perfect, especially for the prevention and treatment of catheter-related thrombosis (CRT) caused by carried central venous catheters (CVCs) in lung cancer surgery. Patients and methods: This study included 460 patients with lung cancer undergoing video-assisted thoracic surgery (VATS) in our center from July 2020 to June 2021. Patients were randomized into two groups, and intraoperatively-placed CVCs would be carried to discharge. During hospitalization, the control group was treated with low-molecular-weight heparin (LMWH), and the experimental group with LMWH + intermittent pneumatic compression (IPC). Vascular ultrasound was performed at three time points which included before surgery, before discharge, and one month after discharge. The incidence of VTE between the two groups was studied by the Log-binomial regression model. Results: CRT occurred in 71.7% of the experimental group and 79.7% of the control group. The multivariate regression showed that the risk of developing CRT in the experimental group was lower than in the control group (Adjusted RR = 0.889 [95%CI0.799–0.989], p = 0.031), with no heterogeneity in subgroups (P for Interaction > 0.05). Moreover, the fibrinogen of patients in the experimental group was lower than control group at follow-up (P = 0.019). Conclusion: IPC reduced the incidence of CRT during hospitalization in lung cancer patients after surgery. Trial registration: No. ChiCTR2000034511.
- Open Access
- 2 November 2022
- Published by Springer Nature in Research Square
Postoperative intermittent pneumatic compression for preventing venous thromboembolism in Chinese lung cancer patients: A randomized clinical trial
Background Postoperative lung cancer patients belong to the high-risk group for venous thromboembolism (VTE). The standardized preventive measures for perioperative VTE in lung cancer are not perfect, especially for the prevention and treatment of catheter-related thrombosis (CRT) caused by carried central venous catheters (CVCs) in lung cancer surgery. Patients and Methods: This study included 460 patients undergoing lung cancer surgery in the Department of Thoracic Surgery, First Affiliated Hospital, Army Medical University from July 2020 to June 2021. Patients were randomized into two groups, and intraoperatively-placed CVCs would be carried to discharge. During hospitalization, the control group was treated with low-molecular-weight heparin (LMWH) and the experimental group with LMWH + IPC. Vascular ultrasound was performed at three time points which included before surgery, before discharge, and one month after discharge. The incidence of VTE between two groups were studied by Log-binomial regression model. Results CRT occurred in 71.7% of the experimental group and 79.7% of the control group. The multivariate regression showed that the risk of developing CRT in the experimental group was lower than in the control group (Adjusted RR = 0.889 [95%CI 0.799–0.989], p = 0.031), with no heterogeneity in subgroups (P for Interaction > 0.05). Moreover, the fibrinogen of patients in the experimental group was lower than control group at follow-up (P = 0.019). Conclusion IPC reduced the incidence of CRT during hospitalization in lung cancer patients after surgery. Clinical Trial Registration: No. ChiCTR2000034511
- 2 November 2022
- Published by Springer Nature in Research Square
Open AccessPostoperative intermittent pneumatic compression for preventing venous thromboembolism in Chinese lung cancer patients: A randomized clinical trial
Background Postoperative lung cancer patients belong to the high-risk group for venous thromboembolism (VTE). The standardized preventive measures for perioperative VTE in lung cancer are not perfect, especially for the prevention and treatment of catheter-related thrombosis (CRT) caused by carried central venous catheters (CVCs) in lung cancer surgery. Patients and Methods: This study included 460 patients undergoing lung cancer surgery in the Department of Thoracic Surgery, First Affiliated Hospital, Army Medical University from July 2020 to June 2021. Patients were randomized into two groups, and intraoperatively-placed CVCs would be carried to discharge. During hospitalization, the control group was treated with low-molecular-weight heparin (LMWH) and the experimental group with LMWH + IPC. Vascular ultrasound was performed at three time points which included before surgery, before discharge, and one month after discharge. The incidence of VTE between two groups were studied by Log-binomial regression model. Results CRT occurred in 71.7% of the experimental group and 79.7% of the control group. The multivariate regression showed that the risk of developing CRT in the experimental group was lower than in the control group (Adjusted RR = 0.889 [95%CI 0.799–0.989], p = 0.031), with no heterogeneity in subgroups (P for Interaction > 0.05). Moreover, the fibrinogen of patients in the experimental group was lower than control group at follow-up (P = 0.019). Conclusion IPC reduced the incidence of CRT during hospitalization in lung cancer patients after surgery. Clinical Trial Registration: No. ChiCTR2000034511
- Open Access
- 23 September 2021
- Published by Wiley in Journal of Oncology
- Vol. 2021, 1-8
Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1
Objective. To investigate the clinical significance of the mRNA expression of RRM1, TUBB3, and ERCC1 in non-small-cell lung cancer (NSCLC) tissues for the selection of adjuvant/postoperative chemotherapy regimens. Methods. Patients diagnosed with stage Ib-IIIa NSCLC were enrolled and randomly divided into a control group (undetected group) and an experimental group (detected group) after radical operation. The control group randomly received chemotherapy with gemcitabine plus cisplatin or paclitaxel plus cisplatin. The mRNA expression of RRM1, TUBB3, and ERCC1 was detected in the experimental group before chemotherapy, and based on the detected expression, the chemotherapy regimen of cisplatin plus gemcitabine or cisplatin plus paclitaxel was chosen. The disease-free survival (DFS) of the control group and experimental group was compared. Results. Pathological type, stage, gene expression detection, and treatment method were not significantly correlated with DFS ( ). In the subgroups treated with gemcitabine, the median DFS was 17 months in the detected group and 10.5 months in the undetected group (hazard ratio = 0.2147, 95% confidence interval: 0.07909–0.5827, ). Multivariate regression analysis was performed to analyse whether gene expression detection was independently correlated with DFS in the subgroups treated with gemcitabine ( ). In the detected group, the prognosis of patients with low expression of RRM1 was better than that of patients with high expression of RRM1 after paclitaxel treatment ( ). Conclusions. The selection of chemotherapy regimen based on mRNA expression of the RRM1, TUBB3, and ERCC1 genes may improve selection of candidate patients to receive clinical chemotherapy. However, large-scale prospective clinical studies are needed for in-depth investigation.
- 23 September 2021
- Published by Wiley in Journal of Oncology
- Vol. 2021, 1-8
Open AccessProspective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1
Objective. To investigate the clinical significance of the mRNA expression of RRM1, TUBB3, and ERCC1 in non-small-cell lung cancer (NSCLC) tissues for the selection of adjuvant/postoperative chemotherapy regimens. Methods. Patients diagnosed with stage Ib-IIIa NSCLC were enrolled and randomly divided into a control group (undetected group) and an experimental group (detected group) after radical operation. The control group randomly received chemotherapy with gemcitabine plus cisplatin or paclitaxel plus cisplatin. The mRNA expression of RRM1, TUBB3, and ERCC1 was detected in the experimental group before chemotherapy, and based on the detected expression, the chemotherapy regimen of cisplatin plus gemcitabine or cisplatin plus paclitaxel was chosen. The disease-free survival (DFS) of the control group and experimental group was compared. Results. Pathological type, stage, gene expression detection, and treatment method were not significantly correlated with DFS ( ). In the subgroups treated with gemcitabine, the median DFS was 17 months in the detected group and 10.5 months in the undetected group (hazard ratio = 0.2147, 95% confidence interval: 0.07909–0.5827, ). Multivariate regression analysis was performed to analyse whether gene expression detection was independently correlated with DFS in the subgroups treated with gemcitabine ( ). In the detected group, the prognosis of patients with low expression of RRM1 was better than that of patients with high expression of RRM1 after paclitaxel treatment ( ). Conclusions. The selection of chemotherapy regimen based on mRNA expression of the RRM1, TUBB3, and ERCC1 genes may improve selection of candidate patients to receive clinical chemotherapy. However, large-scale prospective clinical studies are needed for in-depth investigation.
- Open Access
- 22 September 2021
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 59 (5) , 1-16
miR‑383 increases the cisplatin sensitivity of lung adenocarcinoma cells through inhibition of the RBM24‑mediated NF‑κB signaling pathway
The expression of microRNA‑383 (miR‑383) is downregulated in a variety of tumor tissues, and it exhibits antiproliferative activity in non‑small cell lung cancer cells. In the present study, an association between the downregulation of miR‑383 expression and the deletion of chr8p22 in patients with lung adenocarcinoma was identified. The promoting effect of miR‑383 on cisplatin sensitivity was verified both in vivo and in vitro. Additionally, it was revealed that the expression of RNA binding motif protein 24 (RBM24) protein was regulated by and negatively correlated with miR‑383 expression. Ectopic expression of RBM24 or inhibition of miR‑383 decreased the chemosensitivity of parental A549 cells, whereas knockdown of RBM24 in cisplatin‑resistant A549 cells increased chemosensitivity. Mechanistically, miR‑383 interfered with the activation of nuclear factor κB (NF‑κB) signaling through repression of RBM24‑mediated phosphorylation of Rel‑like domain‑containing protein A and inhibitor α of NF‑κB. Taken together, the downregulation of miR‑383 induced RBM24 expression, which was mediated through the activation of NF‑κB signaling, to contribute to chemotherapy resistance in lung adenocarcinoma cells. The results of the present study highlight potential therapeutic targets for the clinical reversal of the chemotherapy resistance in lung adenocarcinoma.
- 22 September 2021
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 59 (5) , 1-16
Open AccessmiR‑383 increases the cisplatin sensitivity of lung adenocarcinoma cells through inhibition of the RBM24‑mediated NF‑κB signaling pathway
The expression of microRNA‑383 (miR‑383) is downregulated in a variety of tumor tissues, and it exhibits antiproliferative activity in non‑small cell lung cancer cells. In the present study, an association between the downregulation of miR‑383 expression and the deletion of chr8p22 in patients with lung adenocarcinoma was identified. The promoting effect of miR‑383 on cisplatin sensitivity was verified both in vivo and in vitro. Additionally, it was revealed that the expression of RNA binding motif protein 24 (RBM24) protein was regulated by and negatively correlated with miR‑383 expression. Ectopic expression of RBM24 or inhibition of miR‑383 decreased the chemosensitivity of parental A549 cells, whereas knockdown of RBM24 in cisplatin‑resistant A549 cells increased chemosensitivity. Mechanistically, miR‑383 interfered with the activation of nuclear factor κB (NF‑κB) signaling through repression of RBM24‑mediated phosphorylation of Rel‑like domain‑containing protein A and inhibitor α of NF‑κB. Taken together, the downregulation of miR‑383 induced RBM24 expression, which was mediated through the activation of NF‑κB signaling, to contribute to chemotherapy resistance in lung adenocarcinoma cells. The results of the present study highlight potential therapeutic targets for the clinical reversal of the chemotherapy resistance in lung adenocarcinoma.
- Open Access
- 31 August 2021
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1) , 1-19
CIRP promotes the progression of non-small cell lung cancer through activation of Wnt/β-catenin signaling via CTNNB1
Background: Cold-inducible RNA binding protein (CIRP) is a newly discovered proto-oncogene. In this study, we investigated the role of CIRP in the progression of non-small cell lung cancer (NSCLC) using patient tissue samples, cultured cell lines and animal lung cancer models. Methods: Tissue arrays, IHC and HE staining, immunoblotting, and qRT-PCR were used to detect the indicated gene expression; plasmid and siRNA transfections as well as viral infection were used to manipulate gene expression; cell proliferation assay, cell cycle analysis, cell migration and invasion analysis, soft agar colony formation assay, tail intravenous injection and subcutaneous inoculation of animal models were performed to study the role of CIRP in NSCLC cells; Gene expression microarray was used to select the underlying pathways; and RNA immunoprecipitation assay, biotin pull-down assay, immunopurification assay, mRNA decay analyses and luciferase reporter assay were performed to elucidate the mechanisms. The log-rank (Mantel-Cox) test, independent sample T-test, nonparametric Mann-Whitney test, Spearman rank test and two-tailed independent sample T-test were used accordingly in our study. Results: Our data showed that CIRP was highly expressed in NSCLC tissue, and its level was negatively correlated with the prognosis of NSCLC patients. By manipulating CIRP expression in A549, H460, H1299, and H1650 cell lines, we demonstrated that CIRP overexpression promoted the transition of G1/G0 phase to S phase and the formation of an enhanced malignant phenotype of NSCLC, reflected by increased proliferation, enhanced invasion/metastasis and greater tumorigenic capabilities both in vitro and in vivo. Transcriptome sequencing further demonstrated that CIRP acted on the cell cycle, DNA replication and Wnt signaling pathway to exert its pro-oncogenic action. Mechanistically, CIRP directly bound to the 3′- and 5′-UTRs of CTNNB1 mRNA, leading to enhanced stability and translation of CTNNB1 mRNA and promoting IRES-mediated protein synthesis, respectively. Eventually, the increased CTNNB1 protein levels mediated excessive activation of the Wnt/β-catenin signaling pathway and its downstream targets C-myc, COX-2, CCND1, MMP7, VEGFA and CD44. Conclusion: Our results support CIRP as a candidate oncogene in NSCLC and a potential target for NSCLC therapy.
- 31 August 2021
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1) , 1-19
Open AccessCIRP promotes the progression of non-small cell lung cancer through activation of Wnt/β-catenin signaling via CTNNB1
Background: Cold-inducible RNA binding protein (CIRP) is a newly discovered proto-oncogene. In this study, we investigated the role of CIRP in the progression of non-small cell lung cancer (NSCLC) using patient tissue samples, cultured cell lines and animal lung cancer models. Methods: Tissue arrays, IHC and HE staining, immunoblotting, and qRT-PCR were used to detect the indicated gene expression; plasmid and siRNA transfections as well as viral infection were used to manipulate gene expression; cell proliferation assay, cell cycle analysis, cell migration and invasion analysis, soft agar colony formation assay, tail intravenous injection and subcutaneous inoculation of animal models were performed to study the role of CIRP in NSCLC cells; Gene expression microarray was used to select the underlying pathways; and RNA immunoprecipitation assay, biotin pull-down assay, immunopurification assay, mRNA decay analyses and luciferase reporter assay were performed to elucidate the mechanisms. The log-rank (Mantel-Cox) test, independent sample T-test, nonparametric Mann-Whitney test, Spearman rank test and two-tailed independent sample T-test were used accordingly in our study. Results: Our data showed that CIRP was highly expressed in NSCLC tissue, and its level was negatively correlated with the prognosis of NSCLC patients. By manipulating CIRP expression in A549, H460, H1299, and H1650 cell lines, we demonstrated that CIRP overexpression promoted the transition of G1/G0 phase to S phase and the formation of an enhanced malignant phenotype of NSCLC, reflected by increased proliferation, enhanced invasion/metastasis and greater tumorigenic capabilities both in vitro and in vivo. Transcriptome sequencing further demonstrated that CIRP acted on the cell cycle, DNA replication and Wnt signaling pathway to exert its pro-oncogenic action. Mechanistically, CIRP directly bound to the 3′- and 5′-UTRs of CTNNB1 mRNA, leading to enhanced stability and translation of CTNNB1 mRNA and promoting IRES-mediated protein synthesis, respectively. Eventually, the increased CTNNB1 protein levels mediated excessive activation of the Wnt/β-catenin signaling pathway and its downstream targets C-myc, COX-2, CCND1, MMP7, VEGFA and CD44. Conclusion: Our results support CIRP as a candidate oncogene in NSCLC and a potential target for NSCLC therapy.
- Open Access
- 10 June 2021
- Published by Atlantis Press SARL
- p. 485-489
Reflection on Professional Qualification and Training for Talents of Internationalization of Traditional Chinese Medicine
- 10 June 2021
- Published by Atlantis Press SARL
- p. 485-489
Open AccessReflection on Professional Qualification and Training for Talents of Internationalization of Traditional Chinese Medicine
- Open Access
- 13 April 2021
- Published by Springer Nature in Research Square
CIRP Promotes the Progression of Non-small Cell Lung Cancer Through Activation of Wnt/β-catenin Signaling via CTNNB1
Background: Cold-inducible RNA binding protein (CIRP) is a newly discovered proto-oncogene. In this study, we investigated the role of CIRP in the progression of non-small cell lung cancer (NSCLC) using clinic samples, cultured cell lines and animal lung cancer models. Methods: Tissue arrays, IHC and HE staining, immunoblotting, and qRT-PCR were used to detect the indicated gene expression; Plasmid and siRNA transfections as well as viral infection were used to manipulate gene expression; Cell proliferation assay, cell cycle analysis, cell migration and invasion analysis, soft agar colony formation assay, tail intravenous injecting and subcutaneously inoculating of animal models were performed to study the role of CIRP in NSCLC cells; Gene expression microarray was used to select the underlying pathways; RNA immunoprecipitation assay, biotin pull-down assay, immuno-purification assay, mRNA decay analyses and luciferase reporter assay were performed to elucidate the mechanisms. The log-rank (Mantel-Cox) test, independent sample T test, the nonparametric Mann-Whitney test, spearman rank test and two-tailed independent sample T-test were used accordingly in our study. Results: Our data showed that CIRP was highly expressed in NSCLC tissue, and its level was negatively correlated with the prognosis of NSCLC patients. By manipulating CIRP expression in A549, H460, H1299, and H1650 cell lines, we demonstrated that CIRP overexpression promoted the transition of G1/G0 phase to S phase and the formation of enhanced malignant phenotype of NSCLC, reflected by increased proliferation, enhanced invasion/metastasis and greater tumorigenic capabilities both in vitro and in vivo. Transcriptome sequencing further demonstrated that CIRP acted on cell cycle, DNA replication and Wnt signaling pathway to exert its pro-oncogenic action. Mechanistically, CIRP directly bound to the 3’- and 5'-UTR of CTNNB1 mRNA, leading to enhanced stability and translation of CTNNB1 mRNA and promote IRES-mediated protein synthesis, respectively. Eventually, the increased CTNNB1 protein levels mediated excessive activation of the Wnt/β-Catenin signaling pathway and its downstream C-myc, COX-2, CCND1, MMP7, VEGFA and CD44. Conclusion: Our results support CIRP as a candidate oncogene in NSCLC and a potential target for NSCLC therapy.
- 13 April 2021
- Published by Springer Nature in Research Square
Open AccessCIRP Promotes the Progression of Non-small Cell Lung Cancer Through Activation of Wnt/β-catenin Signaling via CTNNB1
Background: Cold-inducible RNA binding protein (CIRP) is a newly discovered proto-oncogene. In this study, we investigated the role of CIRP in the progression of non-small cell lung cancer (NSCLC) using clinic samples, cultured cell lines and animal lung cancer models. Methods: Tissue arrays, IHC and HE staining, immunoblotting, and qRT-PCR were used to detect the indicated gene expression; Plasmid and siRNA transfections as well as viral infection were used to manipulate gene expression; Cell proliferation assay, cell cycle analysis, cell migration and invasion analysis, soft agar colony formation assay, tail intravenous injecting and subcutaneously inoculating of animal models were performed to study the role of CIRP in NSCLC cells; Gene expression microarray was used to select the underlying pathways; RNA immunoprecipitation assay, biotin pull-down assay, immuno-purification assay, mRNA decay analyses and luciferase reporter assay were performed to elucidate the mechanisms. The log-rank (Mantel-Cox) test, independent sample T test, the nonparametric Mann-Whitney test, spearman rank test and two-tailed independent sample T-test were used accordingly in our study. Results: Our data showed that CIRP was highly expressed in NSCLC tissue, and its level was negatively correlated with the prognosis of NSCLC patients. By manipulating CIRP expression in A549, H460, H1299, and H1650 cell lines, we demonstrated that CIRP overexpression promoted the transition of G1/G0 phase to S phase and the formation of enhanced malignant phenotype of NSCLC, reflected by increased proliferation, enhanced invasion/metastasis and greater tumorigenic capabilities both in vitro and in vivo. Transcriptome sequencing further demonstrated that CIRP acted on cell cycle, DNA replication and Wnt signaling pathway to exert its pro-oncogenic action. Mechanistically, CIRP directly bound to the 3’- and 5'-UTR of CTNNB1 mRNA, leading to enhanced stability and translation of CTNNB1 mRNA and promote IRES-mediated protein synthesis, respectively. Eventually, the increased CTNNB1 protein levels mediated excessive activation of the Wnt/β-Catenin signaling pathway and its downstream C-myc, COX-2, CCND1, MMP7, VEGFA and CD44. Conclusion: Our results support CIRP as a candidate oncogene in NSCLC and a potential target for NSCLC therapy.